Novo Nordisk A/S – Annual report – 31 December 2025
Industry: pharmaceuticals
1.2 Changes in accounting policies and disclosures (extract)
IFRS 18 implementation
IFRS 18 will revise the presentation of Novo Nordisk’s Income statement, mainly due to the classification of ‘financial income’ and ‘financial expenses’ into three new line items: ‘operating financial income and expenses’, ‘investment income’ and ‘interest expenses’. This reclassification will result in a difference between the IAS 1 operating profit reported in prior periods and the new IFRS 18-defined operating profit, mainly due to the inclusion of operating foreign exchange differences from intragroup balances and related hedging activities. Reported net results remain unaffected. Further, IFRS 18 is expected to introduce a new note with ‘management-defined performance measures’ in the audited section of the financial statements, as well as introduce additional disclosures. ‘Goodwill’ is presented as a separate line item in the balance sheet with effect from 2025 in line with IFRS 18 requirements.
Accounts examples 